



(51) International Patent Classification:

C07D 401/14 (2006.01) C07D 213/82 (2006.01)

C07D 401/04 (2006.01) A61K 31/4439 (2006.01)

C07D 403/10 (2006.01) A61P 35/00 (2006.01)

(21) International Application Number:

PCT/IB2013/053768

(22) International Filing Date:

9 May 2013 (09.05.2013)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/647,174 15 May 2012 (15.05.2012) US

61/790,967 15 March 2013 (15.03.2013) US

(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): DODD, Stephanie Kay [US/US]; Novartis Institutes for BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). FURET, Pascal [FR/CH]; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). GROTZFELD, Robert Martin [DE/CH]; Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056 Basel (CH). JONES, Darryl Brynley [GB/CH]; Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056 Basel (CH). MANLEY, Paul [GB/CH]; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). MARZINZIK, Andreas [DE/CH]; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). PELLE, Xavier Francois Andre [FR/CH]; Novartis Pharma AG, Forum 1 Novartis Campus, CH-4056 Basel (CH). SALEM, Bahaa

[FR/CH]; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH). SCHOEPPFER, Joseph [CH/CH]; Novartis Pharma AG, Werk Klybeck Postfach, CH-4002 Basel (CH).

(74) Common Representative: NOVARTIS AG; Lichtstrasse 35, CH-4056 Basel (CH).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: BENZAMIDE DERIVATIVES FOR INHIBITING THE ACTIVITY OF ABL1, ABL2 AND BCR-ABL1



(57) Abstract: The present invention relates to compounds of formula (I): in which Y, Y₁, R₁, R₂, R₃ and R₄ are defined in the Summary of the Invention; capable of inhibiting the activity of BCR-ABL1 and mutants thereof. The invention further provides a process for the preparation of compounds of the invention, pharmaceutical preparations comprising such compounds and methods of using such compounds in the treatment of cancers.